Undisclosed hospital granted limited-use permit to treat Covid patients with Ivermectin

THE Food and Drug Administration (FDA) has allowed the “compassionate” use of anti-parasitic drug Ivermectin to treat Covid-19.

In an interview with PTV on Thursday, FDA Director General Eric Domingo said they issued the compassionate use special permit (CSP) to an unnamed hospital to use the drug to treat its Covid-19 patients.

“The application was granted today [April 8],” Domingo said.

FDA did not disclose the name of the said hospital, citing patient privacy, which comes with issued CSPS.

CSP is required before an unregistered drug, medical device or food product can be locally used.

Currently, FDA said it noted two parties, one of which is Lloyd Laboratories Inc., are now applying for the certificate of product registration for their respective Ivermectin products.

“They [applicants] were given the list of requirements that must be submitted before their application can be evaluated [by FDA],” Domingo said.

“We are not against the use of Ivermectin, but it should be registered and go through the necessary process [with FDA] to ensure the quality of the drug before it is given to people,” Domingo added.

Some lawmakers are pushing for the use of Ivermectin, which is currently being used to treat animals with parasites, for Covid-19 patients.

This despite the World Health Organization warning that there is currently no available data that Ivermectin can be used to treat Covid-19.